Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm
From MaRDI portal
Publication:6628202
DOI10.1002/sim.9201zbMATH Open1546.62632MaRDI QIDQ6628202
Unnamed Author, Jeremy Michael George Taylor, Michael R. Elliott
Publication date: 29 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
Cites Work
- Unnamed Item
- Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy
- Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials
- Surrogate Measures and Consistent Surrogates
- What Are the Limits of Posterior Distributions Arising From Nonidentified Models, and Why Should We Care?
- Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials
- Principal Stratification in Causal Inference
- Evaluating Candidate Principal Surrogate Endpoints
- Estimating Vaccine Efficacy From Secondary Attack Rates
- A Bayesian Approach to Improved Estimation of Causal Effect Predictiveness for a Principal Surrogate Endpoint
- Bayesian Inference for the Causal Effect of Mediation
- A framework for Bayesian nonparametric inference for causal effects of mediation
- Augmented Designs to Assess Immune Response in Vaccine Trials
- Sensitivity Analyses Comparing Outcomes Only Existing in a Subset Selected Post‐Randomization, Conditional on Covariates, with Application to HIV Vaccine Trials
- Causal Vaccine Effects on Binary Postinfection Outcomes
- Simultaneous inference of treatment effect modification by intermediate response endpoint principal strata with application to vaccine trials
Related Items (3)
Assessing heterogeneity in surrogacy using censored data ⋮ Surrogacy validation for time-to-event outcomes with illness-death frailty models ⋮ An information-theoretic approach for the assessment of a continuous outcome as a surrogate for a binary true endpoint based on causal inference: application to vaccine evaluation
This page was built for publication: Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm